Table 1.
The baseline characteristics of the seven patients in our hospital
| Patient | Gender | Previous Regimen No | Salvage Chemotherapy | Esomeprazole | Cycles | Objective Response |
|---|---|---|---|---|---|---|
| Case 1 | Male | 1 | Irinotecan | 120 mg, for 2 days | 3 | PD |
| Case 2 | Male | 2 | Docetaxel | 120 mg, for 2 days | 2 | SD |
| Case 3 | Male | 1 | Irinotecan | 120 mg, for 2 days | 3 | PD |
| Case 4 | Male | 1 | Docetaxel | 120 mg, for 2 days | 9 | SD |
| Case 5 | Female | 1 | Docetaxel | 120 mg, for 2 days | 6 | SD |
| Case 6 | Male | 2 | Irinotecan | 60 mg, for 6 days | 5 | PR |
| Case 7 | Male | 1 | 5FU/LV+Oxaliplatin | 60 mg, for 6 days | 5 | PR |